



Updated: February 2021

FACT SHEET

At a Glance*

Launched in: **2006**

Currently working with: **27 countries**

USAID Investment

2.8 billion treatments delivered

1.4 billion people treated

\$26 billion leveraged in donated drugs

7 million individuals trained strengthening the expertise and capacity of country partners

Health Impact

10 USAID-supported countries have eliminated at least one NTD as a public health problem

People no longer requiring treatment for lymphatic filariasis: **315 million**

People no longer requiring treatment for trachoma: **151 million**

People no longer requiring treatment for onchocerciasis: **10 million**

The Future


15 countries will eliminate at least one NTD as a public health problem within 5 years

12 USAID-supported countries are developing NTD sustainability plans


Neglected Tropical Diseases

Neglected tropical diseases (NTDs) cause illness and lifelong disabilities for more than a billion of the poorest and most marginalized people worldwide. Not addressing NTDs traps individuals and communities in poverty, undermines growth and development, and impairs progress towards achieving global health and development goals. For 15 years, the Agency has supported more than 30 countries to combat five of the most common NTDs.

USAID targets **five** of the most common NTDs that have proven, cost-effective health interventions:



Lymphatic Filariasis
(elephantiasis)



Blinding Trachoma



Onchocerciasis
(river blindness)



Schistosomiasis
(snail fever)



Soil Transmitted Helminths
(hookworm, roundworm, whipworm)

Our Objectives

The United States Agency for International Development (USAID) works alongside endemic countries and with global, regional, and in-country partners to improve health and end NTDs. USAID's NTD Program has four key objectives.

Key objectives and approaches to accelerate progress on ending NTDs:



Controlling & eliminating diseases

- **Mapping** to find communities at-risk of these NTDs
- **Treating** at-risk communities with safe, effective, donated medicines — treating for more than one disease at a time where appropriate
- **Measuring** progress and documenting impact of the control and elimination of NTDs



Strengthening the scientific & program evidence base

- **Investing in operational research** to generate and advance evidence that can then be used to remove barriers to progress, improve program efficiencies, and protect public health gains
- **Supporting diagnostic innovations** to improve delivery of NTD services, use of program resources, and measuring progress towards control and elimination targets



Supporting sustainable country-led programs

- **Supporting government-developed, multi-sectoral sustainability plans** for NTD prevention and treatment
- **Reinforcing national governance** of NTD programs
- **Strengthening health systems** to deliver NTD services



Strengthening & expanding partnerships

- **Partnering** with host governments, pharmaceutical companies, private and government donors, non-governmental organizations, and researchers

*Cumulative results from 2006 to 2019


Results Over the Years

	FY 2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Value of Drug Donations by Year		\$404 million	\$507 million	\$577 million	\$686 million	\$949 million	\$1 billion	\$2.5 billion	\$2.1 billion	\$2.2 billion	\$4.6 billion	\$3.3 billion	\$3.2 billion	\$3.7 billion
Number of Treatments Delivered by Year	Program Begins	36 million	58 million	130 million	160 million	208 million	244 million	233 million	239 million	299 million	390 million	318 million	268 million	194 million

Private Sector Donations

Our success is underpinned by a dynamic public-private partnership with the pharmaceutical industry, which enables USAID to carry out the largest integrated NTD program in the world, ensuring that treatments reach those in need. Leading pharmaceutical companies have made unprecedented pledges to tackle the most common NTDs by providing drugs free of charge.

- Eisai Co., Ltd.
- Johnson & Johnson
- Merck KGaA
- GlaxoSmithKline
- Merck & Co. Inc.
- Pfizer



To date: Every \$1 invested by the U.S. Government leverages \$26 in donated medicines for mass treatment campaigns totalling \$26 BILLION in value

Where We Work

Country Successes

USAID-supported countries that have **eliminated at least one disease**, verified by the WHO:
Lymphatic Filariasis: Cambodia (2016), Togo (2017), Vietnam (2018)
Onchocerciasis: Colombia (2013), Ecuador (2014), Mexico (2015), Guatemala (2016)
Trachoma: Cambodia (2017), Laos (2017), Nepal (2018), Ghana (2018)

USAID-supported country governments that have completed an NTD sustainability plan:
 Ivory Coast (2020), Senegal (2021), Uganda (2021)

